Home » Stocks » GBT

Global Blood Therapeutics, Inc. (GBT)

Stock Price: $47.49 USD -0.85 (-1.76%)
Updated Jan 26, 2021 4:00 PM EST - Market closed
After-hours: $47.45 -0.04 (-0.08%) Jan 26, 5:59 PM
Market Cap 2.93B
Revenue (ttm) 84.62M
Net Income (ttm) -281.72M
Shares Out 61.57M
EPS (ttm) -4.62
PE Ratio n/a
Forward PE n/a
Dividend n/a
Dividend Yield n/a
Trading Day January 26
Last Price $47.49
Previous Close $48.34
Change ($) -0.85
Change (%) -1.76%
Day's Open 48.85
Day's Range 47.21 - 49.25
Day's Volume 1,051,297
52-Week Range 37.65 - 81.82

News

Hide News
  • All
  • Videos
  • Press Releases
  • Conversation
Seeking Alpha - 1 day ago

A recap for my 20/20 Vision is offered for my readers. I will share my concerns about the current market conditions.

Other stocks mentioned: AMPH, AQUA, BBDC, BHVN, CFX, CRHM, HASI, HMHC, LXRX, MNKD, NKTR, NNOX, OBSV, PSNL, PTY, ROAD, SGRY, SP, TAK, UTF, XRM
Seeking Alpha - 4 days ago

Global Blood Therapeutics ended 2020 with a nearly 40% drop in its share price. The pandemic negatively affected the number of Oxbryta prescriptions and therefore Oxbryta sales.

Seeking Alpha - 1 month ago

Since 2017, GBT has come a long way to gain Oxbryta approval for treating sickle cell disease. After over 100% capital gains, the stock gave up some profits as the market is sizing up Oxbryta'...

GlobeNewsWire - 1 month ago

Two Inclacumab Pivotal Phase 3 Clinical Trials Expected to Begin in F irst H alf of 2021

GlobeNewsWire - 1 month ago

Final 72-Week Analyses of Phase 3 HOPE Study Demonstrat e Durable Improvements in Hemoglobin Levels and Significant Improvements in Overall Health Status

Zacks Investment Research - 1 month ago

Global Blood (GBT) reported earnings 30 days ago. What's next for the stock?

GlobeNewsWire - 1 month ago

SOUTH SAN FRANCISCO, Calif., Dec. 02, 2020 (GLOBE NEWSWIRE) -- Global Blood Therapeutics, Inc. (GBT) (NASDAQ: GBT) today announced the initiation of an early access program for voxelotor, in E...

GlobeNewsWire - 2 months ago

SOUTH SAN FRANCISCO, Calif., Nov. 25, 2020 (GLOBE NEWSWIRE) -- Global Blood Therapeutics, Inc. (GBT) (NASDAQ: GBT) today announced that members of the senior management team will participate i...

Seeking Alpha - 2 months ago

GBT has the only approved drug that can completely reverse sickle cell disease, which is affecting over 250k people worldwide. It has been subjected to an unwarranted selloff due to a slower t...

Zacks Investment Research - 2 months ago

Global Blood Therapeutics (GBT) saw a big move last session, as its shares jumped nearly 7% on the day, amid huge volumes.

InvestorPlace - 2 months ago

Global Blood Therapeutics (GBT) news for Friday includes poor results from its third-quarter earnings report sending GBT stock lower. The post Global Blood Therapeutics News: 5 Things for GBT ...

Zacks Investment Research - 2 months ago

Global Blood (GBT) reports a wider-than-expected loss and misses sales estimates in the third quarter of 2020.

Seeking Alpha - 2 months ago

Global Blood Therapeutics, Inc. (GBT) CEO Ted Love on Q3 2020 Results - Earnings Call Transcript

Zacks Investment Research - 2 months ago

Global Blood (GBT) delivered earnings and revenue surprises of -34.72% and -17.26%, respectively, for the quarter ended September 2020. Do the numbers hold clues to what lies ahead for the stock?

GlobeNewsWire - 2 months ago

Achieved Oxbryta ® (voxelotor) net revenues of $ 36. 9 million with more than 1,000 new patient prescriptions in the third quarter and net revenues of $82.5 million through first nine months o...

GlobeNewsWire - 2 months ago

Abstracts Include 72-Week Analysis of Phase 3 HOPE Study Supporting  Long-Term Use of Oxbryta ® ( voxelotor )

GlobeNewsWire - 2 months ago

SOUTH SAN FRANCISCO, Calif., Oct. 29, 2020 (GLOBE NEWSWIRE) -- Global Blood Therapeutics, Inc. (GBT) (NASDAQ: GBT) today announced that it will report third quarter 2020 financial results on T...

GlobeNewsWire - 3 months ago

Real-world effectiveness data on Oxbryta® (voxelotor) in the treatment of sickle cell disease featured as oral presentation

GuruFocus - 3 months ago

Smaller biotechs would make nice additions to pharma companies in similar areas of therapy

Other stocks mentioned: IOVA, RETA
GlobeNewsWire - 3 months ago

SOUTH SAN FRANCISCO, Calif., Oct. 12, 2020 (GLOBE NEWSWIRE) -- Global Blood Therapeutics, Inc. (GBT) (NASDAQ: GBT) announced today it has received the 2020 Rare Impact Award ® for Industry Inn...

GlobeNewsWire - 3 months ago

SOUTH SAN FRANCISCO, Calif., Oct. 05, 2020 (GLOBE NEWSWIRE) -- Global Blood Therapeutics, Inc. (GBT) (NASDAQ: GBT) today announced that on October 1, 2020, the compensation committee of GBT’s ...

GlobeNewsWire - 4 months ago

Keynote Address by U.S. Assistant Secretary for Health Admiral Brett P. Giroir, M.D.

GlobeNewsWire - 4 months ago

More than 100,000 people age 12 years and older with sickle cell disease (SCD) in Bahrain, Kuwait, Oman, Qatar, Saudi Arabia, and the United Arab Emirates

Zacks Investment Research - 4 months ago

Global Blood (GBT) reported earnings 30 days ago. What's next for the stock?

Benzinga - 5 months ago

Global Blood Therapeutics (NASDAQ: GBT) shares are trading higher on Tuesday after Raymond James initiated coverage on the company's stock with an Outperform rating and announced a $115 price ...

Seeking Alpha - 5 months ago

Global Blood Therapeutics: Investment Risk Diminishing As Oxbryta Outperforms

Seeking Alpha - 5 months ago

Global Blood Therapeutics, Inc. (GBT) CEO Ted Love on Q2 2020 Results - Earnings Call Transcript

Zacks Investment Research - 5 months ago

Global Blood (GBT) delivered earnings and revenue surprises of 27.12% and 67.11%, respectively, for the quarter ended June 2020. Do the numbers hold clues to what lies ahead for the stock?

GlobeNewsWire - 5 months ago

Achieved Oxbryta® (voxelotor) net revenues of $31.5 million, with approximately 1,000 new patient prescriptions     

Zacks Investment Research - 5 months ago

Seven top-ranked companies are poised to beat on earnings today after the closing bell.

Other stocks mentioned: CWH, FISV, FSLY, MED, RMD, XEC
GlobeNewsWire - 5 months ago

SOUTH SAN FRANCISCO, Calif., July 29, 2020 (GLOBE NEWSWIRE) -- Global Blood Therapeutics, Inc. (GBT) (NASDAQ: GBT) today announced that it will report second quarter 2020 financial results o...

The Motley Fool - 6 months ago

Here are the best biotech stocks for investors looking for market-beating performance.

Other stocks mentioned: MESO, OVID
Benzinga - 6 months ago

Shares of Global Blood Therapeutics Inc (NASDAQ: GBT) have materially underperformed the broader biotech group, rendering its valuation attractive, according to Goldman Sachs.

GlobeNewsWire - 7 months ago

SOUTH SAN FRANCISCO, Calif., June 25, 2020 (GLOBE NEWSWIRE) -- Global Blood Therapeutics, Inc. (GBT) (NASDAQ: GBT) today announced that five U.S. nonprofit organizations serving the sickle c...

Zacks Investment Research - 7 months ago

Global Blood (GBT) plans to seek approval for Oxbryta tablets to treat hemolytic anemia in SCD patients aged 12 years and older in Europe.

GlobeNewsWire - 7 months ago

Intends to seek full marketing authorization for Oxbryta to treat hemolytic anemia in sickle cell disease

Investors Business Daily - 7 months ago

Global Blood Therapeutic sees its Relative Strength Rating move into the 80-plus level.

Zacks Investment Research - 7 months ago

Global Blood (GBT) seeks label expansion of Oxbryta for the treatment of SCD in children aged 4 to 11 years.

GlobeNewsWire - 7 months ago

New Drug Application submission, including new age-appropriate formulation, planned by mid-2021

Zacks Investment Research - 7 months ago

Global Blood (GBT) reported earnings 30 days ago. What's next for the stock?

The Motley Fool - 7 months ago

Here's why it is now a great opportunity to buy a company making an innovative therapy for patients with sickle cell disease.

Zacks Investment Research - 8 months ago

Global Blood Therapeutics (GBT) has seen solid earnings estimate revision activity over the past month, and belongs to a strong industry as well.

GlobeNewsWire - 8 months ago

SOUTH SAN FRANCISCO, Calif., May 07, 2020 (GLOBE NEWSWIRE) -- Global Blood Therapeutics, Inc. (GBT) (NASDAQ: GBT) today announced that on May 1, 2020, the compensation committee of GBT’s boa...

Seeking Alpha - 8 months ago

Global Blood Therapeutics, Inc. (GBT) CEO Ted Love on Q1 2020 Results - Earnings Call Transcript

Zacks Investment Research - 8 months ago

Global Blood (GBT) delivered earnings and revenue surprises of 18.37% and 268.91%, respectively, for the quarter ended March 2020. Do the numbers hold clues to what lies ahead for the stock?

Zacks Investment Research - 8 months ago

Global Blood (GBT) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.

The Motley Fool - 8 months ago

On Wednesday, investors will learn the progress of its sickle cell disease drug launch.

The Motley Fool - 9 months ago

Targeted therapies for treating sickle cell disease are finally here after a 60-year wait.

Other stocks mentioned: CRSP, NVS, VRTX
Seeking Alpha - 9 months ago

Global Blood Therapeutics: Key Catalysts Remain As The Search For Clinical Benefit Continues

GlobeNewsWire - 9 months ago

Newly created GBT Community Fund to provide $150,000 in grants to U.S. non-profits addressing the needs of the sickle cell disease community

About GBT

Global Blood Therapeutics, a clinical-stage biopharmaceutical company, engages in the discovery, development, and delivery of treatments for underserved patient communities. It is developing its lead product candidate, Oxbryta (voxelotor) tablets, an oral, once-daily therapy for sickle cell disease (SCD). The company is evaluating Oxbryta that has completed Phase III clinical trial in adult and adolescent patients with SCD. It is also evaluating the safety and pharmacokinetics of single and multiple doses of Oxbryta in a Phase IIa clinical tria... [Read more...]

Industry
Biotechnology
Founded
2011
CEO
Ted Love
Employees
352
Stock Exchange
NASDAQ
Ticker Symbol
GBT
Full Company Profile

Financial Performance

Financial Statements

Analyst Forecasts

According to 20 analysts, the average rating for GBT stock is "Buy." The 12-month stock price forecast is 86.47, which is an increase of 82.08% from the latest price.

Price Target
$86.47
(82.08% upside)
Analyst Consensus: Buy